COMBI-i Regimen Shows Promise for Patients With BRAF V600–Mutant Melanoma
Source: Cancer Network, July 2019
An ongoing trial of an experimental anti–PD-1 antibody, spartalizumab, in combination with the BRAF inhibitor dabrafenib and MEK inhibitor trametinib appears to have a tolerable safety profile and durable objective response rate in previously untreated patients with advanced BRAF V600–mutant melanoma, according to the updated results of COMBI-i (abstract 9531) presented during a poster session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago.
While targeted therapies and immune checkpoint inhibitors have improved outcomes in patients with BRAF V600–positive advanced melanoma, many patients experience disease progression and are in need of new treatments.
“This study is trying to take patients who have the BRAF mutation and offer them both targeted agents and immune therapy at the same time,” said Mario Sznol, MD, of Yale Cancer Center in New Haven, Connecticut, in an interview with Cancer Network.